Loading people...
Kevin Bitterman is a Partner at Atlas Venture based in Cambridge, Massachusetts, where he focuses on early-stage biotechnology investments and biopharmaceutical company formation. Prior to joining the venture capital firm in 2017, he spent thirteen years as a Partner at Polaris Partners directing life sciences investments. He previously served as the founding chief executive officer of Editas Medicine and Morphic Therapeutic, the latter of which was acquired by Eli Lilly for approximately $3.2 billion in July 2024. Bitterman currently holds board director positions at several clinical and preclinical-stage companies, including publicly traded Disc Medicine and Remix Therapeutics, which secured a $60 million financing round in early 2024. Equipped with a doctorate in genetics from Harvard Medical School and an undergraduate degree from Rutgers University, Bitterman centers his career on translating academic research into novel therapeutic platforms.
Kevin Bitterman stands as a distinguished Partner at Atlas Venture, a premier venture capital firm renowned for its significant contributions to the biotechnology and life sciences sectors. At Atlas Venture, Kevin is instrumental in the firm's unique company creation model, actively participating in the founding, incubation, and strategic development of new therapeutic companies from their inception. His work is central to identifying unmet medical needs and building innovative solutions to address them.
Kevin's investment focus is sharply honed on early-stage life sciences, with a particular emphasis on drug discovery and the creation of novel therapeutic platforms. He is deeply involved in the scientific and strategic aspects of company building, working closely with entrepreneurs and scientists to transform cutting-edge research into viable biotech ventures. His expertise spans various therapeutic areas, always with an eye toward disruptive technologies and transformative medicines.
Before joining Atlas Venture in 2017, Kevin honed his skills and insights at Third Rock Ventures, where he served as an Associate and Senior Associate. This experience provided him with a robust foundation in venture capital and company formation within the life sciences. Prior to his venture capital career, Kevin gained valuable industry experience in business development at Warp Drive Bio, a company focused on genomic mining for drug discovery. His academic background is equally impressive, holding a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (MIT) and a B.S. in Chemical Engineering from the University of Massachusetts Amherst. This strong scientific and engineering foundation underpins his analytical approach to evaluating new opportunities.
Throughout his career at Atlas Venture, Kevin Bitterman has been a key player in the creation and growth of numerous successful biotech companies. His notable contributions include involvement with companies such as Kallyope, a neuroscience company; Kymera Therapeutics, a leader in targeted protein degradation; Synlogic, focused on synthetic biology; Celsius Therapeutics, exploring functional genomics; and Disarm Therapeutics, which was acquired by Eli Lilly. He has also been involved with Quench Bio (acquired by AbbVie), Triana Biomedicines, and MOMA Therapeutics, among others. These ventures exemplify his commitment to fostering innovation and delivering impactful therapeutic solutions to patients worldwide. Kevin Bitterman's strategic vision and hands-on approach continue to drive significant advancements in the biotech landscape.
Kevin Bitterman is a Partner at Atlas Venture, a leading venture capital firm specializing in biotechnology and life sciences. He is known for his role in founding and building early-stage therapeutic companies.
Kevin Bitterman primarily invests in early-stage life sciences, focusing on drug discovery, therapeutic development, and the creation of new biotech companies. His work spans various therapeutic areas with an emphasis on innovative solutions.
Kevin Bitterman works as a Partner at Atlas Venture, a prominent venture capital firm with offices in Cambridge, Massachusetts. He joined Atlas Venture in 2017.
